Pathogenic germline variants identified in pNEN patients during genetic testing.

Tara Arouchian, Alexandra Gangi, Ka Wing Fung, Teodora Dumitra, Abrahm Levi, Arsen Osipov, Andrew E Hendifar

Abstract read

In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tara ArouchianSamuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0004-8310-1997

Alexandra GangiDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Ka Wing FungSamuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA.

Teodora DumitraDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Abrahm LeviSamuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA.

Arsen OsipovSamuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA.

Andrew E HendifarSamuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poor outcomes in pancreatic neuroendocrine neoplasms (pNENs) partially result from the inability to identify early-stage disease in patients. Prevention strategies have focused on identifying high-risk patients through genetic susceptibility genes. This study aims to report the incidence of pathogenic germline variants (PGVs) in pNEN. 129 pNEN patients that underwent germline testing with Invitae between September 5, 2019, and February 15, 2022, were retrospectively analyzed. PGVs were found in 14.7% (19/129) of pNENs. PGVs in pancreatitis genes were detected in 7.7% (3/39) of the 39 pNEN patients with an available pancreatitis panel.

Indexed as

DNA repair genesgermline variantspancreatic neuroendocrine neoplasmsprecision medicine

Identifiers

PMID42245232

DOI10.1530/EO-25-0088

PMCPMC13232594

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.